Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pukateine** is a natural aporphine alkaloid found in the bark of the New Zealand tree *Laurelia novae-zelandiae* ("Pukatea"), traditionally used in Māori herbal medicine as an analgesic[3][1]. Its chemical structure is \((R)-11\)-hydroxy-1,2-methylenedioxyaporphine (C\(_{18}\)H\(_{17}\)NO\(_3\)), a pentacyclic molecule with a benzylisoquinoline backbone and aporphine ring system[2][4][5]. Mechanistically, pukateine acts as a **dopamine receptor agonist** (targeting both D1 and D2 subtypes) with submicromolar IC50 values, increases extracellular dopamine, and demonstrates antioxidant properties by inhibiting lipid peroxidation[1]. It does **not inhibit monoamine oxidase** at pharmacologically relevant concentrations[1]. Its primary indication is analgesia (pain relief), though modern development remains investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pukateine.